Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2 Study of BMN 111 to Evaluate Safety, Tolerability, and Efficacy in Children With Achondroplasia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Parent(s) or guardian(s) are willing and able to provide written, signed informed consent~* 5 to 14 years old at end of study~* ACH, documented by clinical grounds, confirmed by genetic testing~* At least 6-month of pretreatment growth assessment in Study 111-901 before study entry, and one standing height at least 6 months prior to screening for 111-202~* Negative pregnancy test at the Screening Visit for females ≥ 10 years old or who have begun menses~* If sexually active, willing to use a highly effective method of contraception while participating in the study~* Ambulatory, able to stand without assistance~* Willing and able to perform all study procedures as physically possible~* Parents/caregivers willing to administer daily injections to the subjects~Additional inclusion Criteria Optional, Open-label Extension Phase:~* Appropriate written informed consent~Exclusion Criteria:~* Hypochondroplasia or short stature condition other than ACH~* Have any of the following:~  * Hypothyroidism or hyperthyroidism~ * Insulin-requiring diabetes mellitus~ * Autoimmune inflammatory disease~ * Inflammatory bowel disease~ * Autonomic neuropathy~ * Recent acute illness associated with volume dehydration not completely resolved prior to the first dose of study drug~* Unstable condition requiring surgical intervention during the study~* Growth plates have fused~* Have a history of any of the following:~  * Renal insufficiency, defined as creatinine \> 2 mg/dl~ * Anemia~ * Baseline systolic BP \< 75 mm Hg or recurrent symptomatic hypotension or recurrent symptomatic hypotension, recurrent symptomatic orthostatic hypotension~ * Cardiac or vascular disease, including the following:~    * Cardiac dysfunction (abnormal echocardiogram \[ECHO\] including left ventricle \[LV\] mass) at Screening Visit~   * Hypertrophic cardiomyopathy~   * Pulmonary Hypertension~   * Congenital heart disease with ongoing cardiac dysfunction~   * Cerebrovascular disease~   * Aortic insufficiency~   * Clinically significant atrial or ventricular arrhythmias~* Have an ECG showing any of the following:~  * Right or left atrial enlargement or ventricular hypertrophy~ * PR (period of time from the beginning of atrial depolarization until the beginning of ventricular depolarization) interval \> 200 msec~ * QRS (The Q, R, and S heart waves that are measured on an electrocardiogram) interval \> 110 msec~ * Corrected QTc-F (Measure of the corrected time between the start of the Q wave and end of the T wave in the heart's electrical cycle) \> 450 msec~ * Second- or third-degree atrioventricular block~* Documented Vitamin D deficiency~* Require any investigational agent prior to completion of study period~* Have received another investigational product or investigational medical device within 30 days before the Screening visit~* Use of any other investigational product or investigational medical device for the treatment of ACH or short stature~* Current chronic therapy with antihypertensive medications, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers, diuretics, beta-blockers, calcium-channel blockers, cardiac glycosides, systemic anticholinergic agents, any medication that may impair or enhance compensatory tachycardia, diuretics, or other drugs known to alter renal or tubular function~* Treatment with growth hormone, IGF-1 (Insulin-like growth factor), or anabolic steroids in the previous 6 months or long-term treatment (\> 3 months) at any time~* Long-term treatment (\> 1 month) with oral corticosteroids~* Concomitant medication that prolongs the QT/QTc-F interval within 14 days or 5 half-lives, whichever is longer, before the Screening visit~* Pregnant or breastfeeding at the Screening Visit or planning to become pregnant (self or partner) at any time during the study~* Limb-lengthening or bone-related surgery \< 18 months prior to study enrollment~* Had a fracture of the long bones or spine within 6 months prior to screening (except for fracture of digits or toes)~* AST (Aspartate Transaminase) or ALT (Alanine Transaminase) at least 3x upper limit of normal (ULN) or total bilirubin at least 2x ULN~* Evidence of severe sleep apnea requiring surgery or new initiation of CPAP (Continuous positive airway pressure).~* History of malignancy and chemotherapy/radiation or currently under work-up for suspected malignancy~* Known hypersensitivity to BMN 111 or its excipients~* Have a condition or circumstance that, in the view of the Investigator, places the subject at high risk for poor treatment compliance or for not completing the study~* Concurrent disease or condition that would interfere with study participation or safety~* Have abnormal findings on baseline clinical hip exam or imaging assessments that are determined to be clinically significant as determined by the PI.~* Have a history of hip surgery or severe hip dysplasia~* Have a history of clinically significant hip injury in the 30 days prior to screening.~* History of slipped capital femoral epiphysis or avascular necrosis of the femoral head.~* Are unable to lie flat when in prone position~Additional Exclusion Criteria for Optional, Open-label Extension Phase:~* Use of restricted therapies during the initial 6 months of the study~* Permanently discontinued BMN 111 during the initial 6 months of the study

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 14 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): Cohort 1: 2.5 ug/kg
- Cohort 2 (Type: EXPERIMENTAL): Cohort 2: 7.5 ug/kg,
- Cohort 3 (Type: EXPERIMENTAL): Cohort 3: 15 ug/Kg
- Cohort 4 (Type: EXPERIMENTAL): Cohort 4: 30 ug/kg

Based on this trial design, predict the completion outcome and termination type (if applicable).